Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Medigen Vaccine Biologics Corporation (Taiwan)
Homepage:
medigenvac.com
Alternate name:
Medigen Vaccine Biologics Corporation
ROR:
05fk7vc32
OpenAlex ID:
I4405268030
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
2020
·
Tsun-Yung Kuo
, Meei-Yun Lin
, et al.
·
Scientific Reports
·
164
PDF
Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan
2021
·
Szu-Min Hsieh
, Ming-Che Liu
, et al.
·
The Lancet Respiratory Medicine
·
128
PDF
Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study
2021
·
Szu-Min Hsieh
, Wang-Da Liu
, et al.
·
EClinicalMedicine
·
65
PDF
Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial
2022
·
Trong Toan Nguyen
, Cheng-Hsun Chiu
, et al.
·
The Lancet
·
63
CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge
2021
·
Chia-En Lien
, Yi-Jiun Lin
, et al.
·
Scientific Reports
·
42
PDF
Transforming stress program on medical students’ stress mindset and coping strategies: a quasi-experimental study
2023
·
Tan Nguyen
, Christy Pu
, et al.
·
BMC Medical Education
·
39
PDF
An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay
2022
·
Julio Torales
, Osmar Cuenca-Torres
, et al.
·
Vaccine
·
36
PDF
Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan
2019
·
Li-Min Huang
, Cheng-Hsun Chiu
, et al.
·
Vaccine
·
31
Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study
2022
·
Szu-Min Hsieh
, Shan-Chwen Chang
, et al.
·
Infectious Diseases and Therapy
·
27
An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
2022
·
Josue Antonio Estrada
, Chien-Yu Cheng
, et al.
·
Vaccines
·
20
PDF
Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial
2022
·
Luke Tzu-Chi Liu
, Cheng-Hsun Chiu
, et al.
·
npj Vaccines
·
16
PDF
Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern
2021
·
Chia-En Lien
, Tsun-Yung Kuo
, et al.
·
Clinical Infectious Diseases
·
16
PDF
The presence of substances of the Shewanella strain 0409, isolated from grouper intestine, gives antiviral activity against Betanodavirus in cell cultures and protection of fish
2019
·
Yu-Chi Wu
, Li-Shiuan Chu
, et al.
·
Aquaculture
·
13
Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2
2021
·
Kuan-Ying A. Huang
, Daming Zhou
, et al.
·
Theranostics
·
12
PDF
Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine
2022
·
Yi-Jiun Lin
, Meei-Yun Lin
, et al.
·
Scientific Reports
·
10
PDF
Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial
2023
·
Lila Estephan
, Ying-Chin Lin
, et al.
·
Vaccine
·
8
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
2022
·
Alexander Waits
, Jau-Yuan Chen
, et al.
·
International Journal of Infectious Diseases
·
8
A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV
2022
·
Shu-Hsing Cheng
, Chia En Lien
, et al.
·
Vaccines
·
7
PDF
Spatiotemporal variations and risks assessment of PAH-bound suspended particles across different Asian countries: Insights from multi-city sampling and source apportionment
2025
·
Kai Hsien Chi
, Yen-Shun Hsu
, et al.
·
Environmental Research
·
6
Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P
2022
·
Tsun-Yung Kuo
, Chia En Lien
, et al.
·
The Journal of Infectious Diseases
·
6
PDF
Prescribing antibiotics for children with dengue infection in Taiwan: who are at risk and who are high prescribers?
2024
·
Yi-Jung Shen
, Chia-En Lien
, et al.
·
International Journal for Quality in Health Care
·
5
Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice
2022
·
Shyamala Ganesan
, Hugo Acosta
, et al.
·
PLoS ONE
·
5
PDF
Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901-Beta SARS-CoV-2 Vaccine in Adults: A Phase I, Prospective, Randomized, Open-Labeled Study
2023
·
Chia En Lien
, Ming-Che Liu
, et al.
·
Vaccines
·
4
PDF
Ammonium produced from Shewanella strain 0409 contributes to antiviral activity against Betanodavirus
2020
·
Yu-Chi Wu
, Chia-Hong Tsai
, et al.
·
Aquaculture
·
4
The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial
2019
·
Aristine Cheng
, Szu-Min Hsieh
, et al.
·
Journal of Microbiology Immunology and Infection
·
4
PDF
Show more works
View as search
Works count:
36
Citation count:
3,640
Year
Topic
Type
